17-LUN-104-HR Multiple Targeted Therapies for Advanced or Metastatic NSCL Harboring Actionable Mutations in Blood

Grants and Contracts Details

StatusFinished
Effective start/end date2/27/18 → 10/21/20

Funding

  • Genentech Inc: $56,764.00